Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOX PARK: Botulinum toxin for refractory upper limb rest tremor in Parkinson's disease
2026-525862-23-00Phase 2Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in Parkinson's disease (PD) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Patient Global Impression-Change (PGI-C) at 6 weeks. Planned start Jul 2026; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2026-525862-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525862-23-00.